Patents by Inventor Steven Pennock

Steven Pennock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adeno-associated virus (AAV) systems for treatment of genetic hearing loss
    Patent number: 12241077
    Abstract: Described herein are codon optimized nucleic acid sequences encoding gap junction protein beta 2 (GJB2), and associated genetic elements, for use in recombinant adeno-associated virus (rAAV)-based gene therapy. The rAAV vectors through which GJB2 is packaged can be used for targeted delivery to patients suffering from genetic hearing loss, including patients with autosomal mutations, recessive or dominant, in the GJB2 gene.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: March 4, 2025
    Assignee: Eli Lilly and Company
    Inventors: Christopher Bartolome, Luis David Jaramillo, Adrian M. Timmers, Steven Pennock, Mark Shearman
  • ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR TREATMENT OF PROGRANULIN ASSOCIATED NEURODEGENERATIVE DISEASES OR DISORDERS
    Publication number: 20240318199
    Abstract: The disclosure provides, in part, optimally-modified progranulin (PGRN) cDNA and associated genetic elements for use in recombinant adeno-associated virus (rAAV)-based gene therapy for neurodegenerative disorders characterized by cognitive disruption, behavioral impairment, and deficient lysosomal storage, including familial frontotemporal dementia (FTD), frontotemporal lobar degeneration (FTLD), neuronal ceroid lipofuscinosis (NCL), or Alzheimer's disease (AD).
    Type: Application
    Filed: September 26, 2023
    Publication date: September 26, 2024
    Inventors: Juan Li, Tanaz Farivar, Savitri Mandapati, Steven Pennock, Mark Shearman, Judith Newmark, Adrian M. Timmers
  • VARIANT ADENO-ASSOCIATED VIRUS (AAV) CAPSID POLYPEPTIDES AND GENE THERAPEUTICS THEREOF FOR TREATMENT OF HEARING LOSS
    Publication number: 20240226330
    Abstract: Described herein are variant adeno-associated virus (AAV) capsid polypeptides and gene therapeutics thereof for use in the treatment or prevention of hearing loss.
    Type: Application
    Filed: May 5, 2023
    Publication date: July 11, 2024
    Inventors: Steven Pennock, Adrian M. Timmers, Mark Shearman, Christopher Bartolome, Wang Xiaobo, Prahav Dinesh Mathur, Phillip M. Uribe, Stephanie Szobota, Bonnie E. Jacques, Alan C. Foster, Fabrice Piu
  • VARIANT ADENO-ASSOCIATED VIRUS (AAV) CAPSID POLYPEPTIDES AND GENE THERAPEUTICS THEREOF FOR TREATMENT OF HEARING LOSS
    Publication number: 20240131189
    Abstract: Described herein are variant adeno-associated virus (AAV) capsid polypeptides and gene therapeutics thereof for use in the treatment or prevention of hearing loss.
    Type: Application
    Filed: May 4, 2023
    Publication date: April 25, 2024
    Inventors: Steven Pennock, Adrian M. Timmers, Mark Shearman, Christopher Bartolome, Wang Xiaobo, Prahav Dinesh Mathur, Phillip M. Uribe, Stephanie Szobota, Bonnie E. Jacques, Alan C. Foster, Fabrice Piu
  • TRIPLE FUNCTION ADENO-ASSOCIATED VIRUS (AAV)VECTORS FOR THE TREATMENT OF C9ORF72 ASSOCIATED DISEASES
    Publication number: 20240067984
    Abstract: The present disclosure provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of C9ORF72 associated diseases, including ALS and FTD.
    Type: Application
    Filed: April 24, 2023
    Publication date: February 29, 2024
    Inventors: Peixin Zhu, Xijia Wang, Steven Pennock, Mark Shearman
  • TRIPLE FUNCTION ADENO-ASSOCIATED VIRUS (AAV)VECTORS FOR THE TREATMENT OF C9ORF72 ASSOCIATED DISEASES
    Publication number: 20210147873
    Abstract: The present disclosure provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of C9ORF72 associated diseases, including ALS and FTD.
    Type: Application
    Filed: October 22, 2020
    Publication date: May 20, 2021
    Inventors: Peixin Zhu, Xijia Wang, Steven Pennock, Mark Shearman
  • ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR TREATMENT OF PROGRANULIN ASSOCIATED NEURODEGENERATIVE DISEASES OR DISORDERS
    Publication number: 20210147872
    Abstract: The disclosure provides, in part, optimally-modified progranulin (PGRN) cDNA and associated genetic elements for use in recombinant adeno-associated virus (rAAV)-based gene therapy for neurodegenerative disorders characterized by cognitive disruption, behavioral impairment, and deficient lysosomal storage, including familial frontotemporal dementia (FTD), frontotemporal lobar degeneration (FTLD), neuronal ceroid lipofuscinosis (NCL), or Alzheimer's disease (AD).
    Type: Application
    Filed: October 22, 2020
    Publication date: May 20, 2021
    Inventors: Juan Li, Tanaz Farivar, Savitri Mandapadi, Steven Pennock, Mark Shearman, Judith Newmark, Adrian Timmers
  • ADENO-ASSOCIATED VIRUS (AAV)VECTORS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES AND DISORDERS
    Publication number: 20210123076
    Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of age-related macular generation and other genetic diseases that affect the cone cells of the retina.
    Type: Application
    Filed: October 22, 2020
    Publication date: April 29, 2021
    Inventors: Mark Shearman, Adrian M Timmers, Judith Newmark, Steven Pennock, Rakshaa Mureli, Chunjuan Song, Lisa Keyes
  • ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR TREATMENT OF GENETIC HEARING LOSS
    Publication number: 20210095313
    Abstract: Described herein are optimally-modified GJB2 cDNA and associated genetic elements for use in recombinant adeno-associated virus (rAAV)-based gene therapy for the treatment of genetic hearing loss.
    Type: Application
    Filed: September 30, 2020
    Publication date: April 1, 2021
    Inventors: Chris Bartolome, Luis David Jaramillo, Adrian Timmers, Steven Pennock, Mark Shearman